1. Home
  2. EPOW vs RNTX Comparison

EPOW vs RNTX Comparison

Compare EPOW & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EPOW
  • RNTX
  • Stock Information
  • Founded
  • EPOW 2014
  • RNTX 2001
  • Country
  • EPOW China
  • RNTX United States
  • Employees
  • EPOW N/A
  • RNTX N/A
  • Industry
  • EPOW Business Services
  • RNTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • EPOW Consumer Discretionary
  • RNTX Health Care
  • Exchange
  • EPOW Nasdaq
  • RNTX Nasdaq
  • Market Cap
  • EPOW 36.5M
  • RNTX 38.9M
  • IPO Year
  • EPOW 2021
  • RNTX N/A
  • Fundamental
  • Price
  • EPOW $1.15
  • RNTX $1.50
  • Analyst Decision
  • EPOW
  • RNTX Buy
  • Analyst Count
  • EPOW 0
  • RNTX 2
  • Target Price
  • EPOW N/A
  • RNTX $10.00
  • AVG Volume (30 Days)
  • EPOW 92.3K
  • RNTX 2.6M
  • Earning Date
  • EPOW 01-01-0001
  • RNTX 11-14-2025
  • Dividend Yield
  • EPOW N/A
  • RNTX N/A
  • EPS Growth
  • EPOW N/A
  • RNTX N/A
  • EPS
  • EPOW N/A
  • RNTX N/A
  • Revenue
  • EPOW $64,997,741.00
  • RNTX N/A
  • Revenue This Year
  • EPOW N/A
  • RNTX N/A
  • Revenue Next Year
  • EPOW N/A
  • RNTX N/A
  • P/E Ratio
  • EPOW N/A
  • RNTX N/A
  • Revenue Growth
  • EPOW 44.28
  • RNTX N/A
  • 52 Week Low
  • EPOW $0.70
  • RNTX $1.04
  • 52 Week High
  • EPOW $1.86
  • RNTX $3.50
  • Technical
  • Relative Strength Index (RSI)
  • EPOW 50.78
  • RNTX 56.35
  • Support Level
  • EPOW $1.15
  • RNTX $1.15
  • Resistance Level
  • EPOW $1.25
  • RNTX $1.52
  • Average True Range (ATR)
  • EPOW 0.06
  • RNTX 0.13
  • MACD
  • EPOW -0.00
  • RNTX 0.01
  • Stochastic Oscillator
  • EPOW 61.11
  • RNTX 68.62

About EPOW Sunrise New Energy Co. Ltd

Sunrise New Energy Co Ltd is engaged in the manufacturing and sale of graphite anode material for EVs and other lithium-ion batteries. The Company's joint venture is in the construction of a manufacturing plant in Guizhou Province. The plant runs on inexpensive electricity from renewable sources that enables the group to be a low-cost and low environmental impact producer of graphite anode material, Its products include GS-1, GS-2, GS-3, GZD-1, GLD-1, and GZ-1.

About RNTX Rein Therapeutics Inc. Common Stock

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

Share on Social Networks: